CytoTools
- Company typePrivate
- Founded2000
- HeadquartersDarmstadt, Germany
- Headcount1–10
- GTM typeB2B
- OfferingServices
CytoTools firmographics
Firmographics- Name
- CytoTools
- Legal name
- bioXXmed AG
- Website
- https://cytotools.de
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
CytoTools industry classification
Industry- Product category
- Biomedical Investment Holding
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industry
- Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF)
Keywords
Where CytoTools is headquartered
LocationHeadquarters
- HQ city
- Darmstadt
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
CytoTools business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Operations, Personnel, Others
CytoTools product offering
Product offeringCore offering
bioXXmed AG operates as a German holding company and active portfolio manager that finances the development of innovative biomedical products for diagnosis, relief, or cure of diseases. The company targets portfolio companies with patented, application-oriented technologies or products with long patent remaining terms, focusing on clinical indications with high Medical Need (unsatisfied therapy standards). Following the completed sale of subsidiary Rancoderm GmbH in March 2026, the company currently has no active projects and is searching for new biomedical investment opportunities.
Product overview
bioXXmed AG operates as a holding company and active portfolio manager in the biomedical sector. Following the sale of its subsidiary Rancoderm GmbH in March 2026, the company currently has no active projects or products. The company's investment focus centers on financing the development of innovative products for diagnosis, relief, or cure of diseases, targeting companies with patented, application-oriented technologies with long patent terms and high medical need in clinical indications. The company is actively seeking new investment opportunities in innovative projects.
Differentiator
Problem solved
Functional benefit
Products and services
- Biomedical portfolio investment management Active portfolio management service that finances the development of innovative biomedical products for diagnosis, relief, or cure of diseases, targeting portfolio companies with patented application-oriented technologies, long patent remaining terms, and high Medical Need clinical indications. Following the March 2026 sale of subsidiary Rancoderm GmbH, the company is seeking new investment opportunities.
Companies that use CytoTools
Customer profileIdeal customer profiles2 records
CytoTools technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
CytoTools partnerships and signals
Strategic signalScale indicators1 record
Recent moves4 records
Expansion highlights3 records
CytoTools competitors and assessment
Company assessmentEmerging players
- PAHCOEF Holding GmbH: Small German healthcare/biomedical holding entity analogous in form to bioXXmed AG — a portfolio-based vehicle with limited operating staff investing in biomedical opportunities — though much smaller and less publicly visible.
- Affimed NV: German-based clinical-stage immuno-oncology company; comparable as a small European biotech operating from the German biotech corridor with similar patient-capital and public-market dynamics.
Broad incumbents
- Dermapharm Holding SE: German specialty pharmaceutical company focused on dermatology and selected other indications; comparable to bioXXmed AG given the dermatology emphasis and German capital-markets footprint, though Dermapharm is a larger commercial operator.
- Evotec SE: German biotech company operating a broad R&D and service platform across multiple therapeutic areas — comparable to bioXXmed AG as a Germany-headquartered life-sciences platform building value through biomedical innovation, though Evotec is far larger and operationally integrated.
- CureVac AG: German biotech AG developing mRNA-based therapies — similar German AG legal structure and biomedical thesis to bioXXmed AG, though at much larger scale post-Nasdaq listing.
- Heidelberg Pharma AG: Heidelberg-based oncology biotech operating as a German AG; comparable geographically and structurally to bioXXmed AG (both Heidelberg AG-listed life-sciences companies), though Heidelberg Pharma is an operating developer rather than a holding/investment vehicle.
Direct peers
- Medigene AG: German AG-listed biotech focused on immunology and oncology; comparable as a small-cap German AG life-sciences entity navigating capital markets, though Medigene is an operator rather than an investment holdco.
- BB Biotech AG: Swiss-listed investment holding company that invests in global biotechnology companies — closely matches bioXXmed AG's biomedical investment holding model, though at much larger scale and listed on the SIX Swiss Exchange.
- Biofrontera AG: German specialty pharma company focused on dermatology — directly comparable to bioXXmed AG's former subsidiary Rancoderm GmbH in therapeutic focus and Heidelberg-area biotech ecosystem roots; both are AG-structured, small-cap German life-sciences companies.
- 4SC AG: German AG-listed small-cap biotech developing treatments in oncology and autoimmune disease; relevant peer as a small, Germany-domiciled AG specialty pharma with similar capital-markets profile to bioXXmed AG.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat1 record
Key risks5 records
Key highlights4 records
Customer concentration
CytoTools social profiles
Digital presenceCytoTools financial estimates
Financial estimateRevenue estimate
Valuation estimate
CytoTools leadership team
Management profileNumber of profiles
Profiles2 records
CytoTools subsidiaries and ownership
Company hierarchySubsidiaries1 record
CytoTools funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CytoTools M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CytoTools
What does CytoTools do?
bioXXmed AG operates as a German holding company and active portfolio manager that finances the development of innovative biomedical products for diagnosis, relief, or cure of diseases. The company targets portfolio companies with patented, application-oriented technologies or products with long patent remaining terms, focusing on clinical indications with high Medical Need (unsatisfied therapy standards). Following the completed sale of subsidiary Rancoderm GmbH in March 2026, the company currently has no active projects and is searching for new biomedical investment opportunities.
Is CytoTools a public or private company?
CytoTools is a private company. It is classified as unknown and is currently operating.
When was CytoTools founded?
CytoTools was founded in 2000. It employs 1 to 10 people.
Where is CytoTools based?
CytoTools is headquartered in Darmstadt, Germany, in the Europe region.
Who are CytoTools's main competitors?
Emerging players on record are PAHCOEF Holding GmbH and Affimed NV. Broad incumbents are Dermapharm Holding SE, Evotec SE, CureVac AG and Heidelberg Pharma AG. Direct peers are Medigene AG, BB Biotech AG, Biofrontera AG and 4SC AG.
Does CytoTools have an API?
No public API is recorded for CytoTools.
What industry is CytoTools in?
CytoTools's product category is Biomedical Investment Holding. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAAAKAF, Process Development & Tech Transfer Services (upstream/downstream). Its NAICS code is 325414 and its SIC code is 2833.